Unitaid takes inspiration from the idea that we are all part of the human family and that no single country can view the well-being of its own people in isolation from others...
Rarely have the odds looked better for ridding the world of HIV/AIDS, tuberculosis, malaria and other deadly infectious diseases...
Unitaid invests in new ways to prevent, diagnose and treat HIV/AIDS, tuberculosis and malaria more quickly, affordably and effectively. We also work to improve access to diagnostics and treatment for HIV co-infections including hepatitis C. We bring the power of new medical discoveries to the people who most need them. Unitaid helps set the stage for the large-scale introduction of new health products. We do this by collaborating with governments, industry, technical agencies, civil society and funding partners.
Unitaid adopted a strategy for 2017 to 2021 to support global efforts to end HIV/AIDS, malaria and tuberculosis, and to help reduce inequality in access to healthcare.Unitaid’s strategic objectives are to foster innovation and create the right conditions for mass introduction of pioneering medicines, diagnostic tests and prevention tools. The strategy follows the Sustainable Development Goal on health, which sets out to promote access to healthcare as a basic human right over the next 15 years.
Unitaid collaborates with global health partners and governments to:
shortcomings in the global response.
smart new ideas to help close the gaps.
the best proposals and fund their development.
full-scale deployment of practical solutions.
Top game-changing investments
In just over 10 years, Unitaid has invested US$ 2.5 billion through 59 grants with key partners across the globe. Below we describe eight flagship projects designed to bolster global efforts to end HIV/AIDS, tuberculosis and malaria.
The Medicines Patent Pool, fully funded by Unitaid, signs licenses for the generic production of a hepatitis C drug.
Unitaid partners with IVCC to develop new insecticides to fight malaria in 16 African countries. US$ 65 million is to be invested over four years.
Unitaid’s Executive Board endorses three areas for intervention to end TB: increased access to better, shorter treatments for drug-resistant TB; better treatments for children; and preventive therapy for those at greatest risk of developing active TB.
Unitaid issues a call for funding proposals to widely introduce better TB treatment for children.
MMV announces a new soluble formulation to protect African children under five who are at high risk of malaria, part of a three-year Unitaid funded project to increase access to seasonal malaria chemoprevention.
Unitaid publishes two reports forecasting rising demand for malaria diagnostics and treatment through 2018.
Unitaid issues a call for innovative proposals to make new, shorter preventive TB treatment regimens more easily available.
At an Executive Board meeting in Paris, Unitaid welcomes former Brazilian Foreign Minister Celso Amorim as the new Unitaid Chair, replacing Philippe Douste-Blazy, Unitaid’s founding Chair.
The UK’s Sarah Boulton is appointed as Vice-Chair.
Unitaid announces it will work with partners to pilot the RTS,S, a malaria vaccine that could have a significant impact on global health.
First patients enrolled in endTB observational trial in Peru to accelerate access to better multidrug-resistant TB treatments. US$ 60 million invested by Unitaid over four years (2015-2019).
Unitaid celebrates its 10-year anniversary
Unitaid invests an additional US$ 14.7 million in the OPP-ERA project led by Solthis to expand access to quality, affordable viral load testing in Western and Central Africa over three years.
Kenya becomes the first country to roll out child-friendly TB medicines nationwide, made available by a US$ 16.6 million Unitaid investment.
Unitaid partners with FIND to improve diagnostics and treatment for hepatitis C in a US$ 38.3 million project over three and a half years.
Unitaid partners with Clinton Health Access Initiative to accelerate introduction of pioneering HIV drugs. US$ 34 million is to be invested in the programme over three years.
Unitaid and ANRS launch an initiative in Cameroon to bring new HIV treatments to Africa.
The UK’s latest Multilateral Development Review gives Unitaid a strong vote of confidence for its innovative work to end HIV, TB and malaria.
Unitaid’s Executive Board approves a US$ 30 million investment on optimisation of ARVs. The four grants are focused on one of the three areas for intervention the Board established in March.
Unitaid’s Executive Board adopts a new five-year strategy to support global efforts to end HIV/AIDS, TB, malaria and hepatitis C and agrees to fund more projects supporting integration in reproductive, maternal, newborn and child health.
Unitaid calls for proposals to create and accelerate the demand for and adoption of HIV self-testing in low- and middle-income countries, particularly among underserved populations at high risk of HIV infection.
Unitaid launches a new call for proposals to help countries take advantage of provisions under global intellectual property rules that allow increased access to affordable medicines in order to safeguard public health.
Unitaid joins WHO in its efforts to mobilize countries and partners to unite to end tuberculosis. This year’s focus is the stigma, discrimination and marginalization that many people with tuberculosis face in low-income countries.
On World Malaria Day, Unitaid’s Executive Board approves three new malaria grants totaling over US$ 72 million. The grants will help prevent malaria deaths among pregnant women and children under five, high-risk groups for the disease.
Unitaid joins experts in calling for new tools to tackle vector-borne diseases at an international vector control conference in Madrid. The event is organized by Unitaid in partnership with ISGlobal, the WHO and the Fundación Ramón Areces.
To accelerate access to better antiretroviral drugs, the government of Kenya and Unitaid announce the introduction of dolutegravir, a new first-line drug for people living with HIV, making Kenya the first African country to introduce the generic version of this drug for routine use. Dolutegravir is a more effective drug, has few side effects, and is administered in one small pill a day.
Unitaid and the Global Fund jointly launch a public awareness campaign in Paris to highlight their dynamic partnership in global health, as well as France’s engagement in the fight against HIV/AIDS, tuberculosis and malaria.
During the G20 summit in Hamburg, Unitaid joins a call by 33 global health organizations for G20 countries to make health a priority, with emphasis on antimicrobial resistance, pandemic preparedness and poverty-related neglected diseases.
The expansion of the HIV Self-Testing Africa (STAR) initiative is announced in Paris at the 9th IAS Conference on HIV Science. Funded by Unitaid, STAR is the largest effort to date to create a thriving market for HIV self-testing in Africa. Evidence from STAR’s first phase showed that more people learn their HIV status when they can test themselves in private.
In Maputo, the government of Mozambique and Unitaid launch TIPTOP, a US$ 50 million project
implemented by Jhpiego to bring lifesaving anti-malarial medication to hard-to-reach pregnant women in four African countries.
Unitaid’s Executive Board approves a pair of grants worth a combined US$ 74 million to prevent the spread of TB in populations most at risk of contracting the disease and to increase TB diagnosis in children.
Unitaid teams up with UNAIDS and other organizations to announce a breakthrough pricing agreement that will allow affordable, high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low- and middle-income countries.
Unitaid is tapped to chair a new working group on innovation and access for the UN’s Interagency Coordination Group on Antimicrobial Resistance, a role that supports global efforts to avert a “post-antibiotic era” in which treatments for common infections no longer work.
Unitaid’s Executive Board approves two grants focused on childhood TB. The grants total US$ 43 million and combine with September’s two TB grants to provide $117 million in new investment to fight the disease.
The Médecins Sans Frontières HCV project, which Unitaid has funded for the past three years, secures a price of US$ 120 for complete hepatitis C treatments. The news is a milestone in the race to eliminate viral hepatitis.
Unitaid and Wits Reproductive Health and HIV Institute launch a US$ 10.6 million project to deliver prevention services, including pre-exposure prophylaxis (PrEP) medication, to adolescent girls and young women in South Africa.
With the University of Bordeaux, Unitaid launches TB-Speed, a four-year research project to cut TB deaths among children by making available fast tests that can be used in remote settings.
For the second year in a row, Unitaid scores an A-plus rating in the UK’s Department for International Development’s (DFID) Annual Review, which sets rigorous performance standards for all projects that the UK financially supports.
Unitaid makes life-saving drugs affordable and accessible. Prices for adult second-line antiretrovirals dropped by 60 percent in 10 years, and more people living with HIV were put on treatment thanks to Unitaid’s efforts.
Unitaid is speeding access to better, shorter treatments for multidrug-resistant tuberculosis (MDR-TB). Unitaid also helped scale up the use of a new, affordable, rapid test for drug-resistant tuberculosis, increasing detection of MDR-TB.
Unitaid has increased access to quality antimalarial drugs and new diagnostic techniques, contributing to a 50 percent reduction in malaria deaths since 2000.
Unitaid is spurring innovation for paediatric treatments by supporting the best new medicines specially adapted for children living with HIV, TB or malaria. Unitaid funded the first tuberculosis drug specially adapted for children, which has been adopted by more than 60 countries worldwide.
In just over ten years, Unitaid has invested close to US$ 2.5 billion through 59 grants with key partners across the globe, to bring better health products to those who need them most.
Unitaid’s current donors are France, the United Kingdom, Brazil, Norway, Chile, the Republic of Korea, Spain and the Bill & Melinda Gates Foundation. A key source of income is innovative financing, specifically the international solidarity levy on airline tickets.
* Includes £88 m of promissory notes translated to US$107.7 m as of 31.12.2016.
**Includes contributions from Cameroon, Democratic Republic of Congo, Guinea, Luxembourg, Madagascar, Mali, Mauritius and Niger.